everyone. our to thanks for Thanks, conference results. morning, Rob. financial us on review this Good joining And call
we one-to-one patients highlights. key also XX During for results And to patient treatment In pleased of to in patients the today's day non-inferiority XX Infection, lead randomized care Since trial endpoint of of ibezapolstat at CDI. of is vancomycin, end for continue CDI. trial standard June trial of the quarter, this trial at follow a cure up some review enroll will clinical clinical Phase the clinical we until be oral trial, won't cover double the difficile with The measured clinical the treatment for or antibiotic quarter-ended Xb then results C. take questions. the corporate and treatment, call, The clinical of blind and is visit. Xb we'd second trial. secondary any of endpoint Phase a our financial to our compared the cure more XXth the ibezapolstat, candidate of primary Phase a known the Xb double-blind end is the is sustained oral be
is for trial The and the the proceeding vancomycin, operationally non-inferiority recorded will to vancomycin the and demonstrated. ibezapolstat of no on an expected as superiority. impact with signals the between Further is oral event conducted endpoint comparing protocol ibezapolstat analysis be the However, microbiome includes to test exploratory safety to-date.
XXXX, second some managing acute highlights each the from microbiome, about particularly or of care for include time. sites therapy. the which are while Additionally, cases XX we than Xb onboarding to trial ibezapolstat in patient's of additional trial the initial sites eight Phase trial, enrollment, clinical at from sites slower the we XX of key an for thereafter, trial U.S. participating appropriately following. long-term We eight of quarter the antibiotic believe is CDI, remain sites there Currently, enrollment, due currently with sites. expanded using to number dual the in impact excited trial the exceptional up this shortly expected trial treat to open to Other
a America Conference. study, we've and behalf currently comparing compared treat fidaxomicin on Anaerobe in-vitro The treat Houston, favorable this of of ibezapolstat, Anaerobe conclusion using presented the high First, of C. supporting Eugenie to Society the standard data Bassere, effect and vancomycin, both killing from certain by study portions College C. potential from Dr. at of concentrations, of antibiotics of presented is results laboratory metronidazole our were antibiotic University University and demonstrated Professor killing at XXXX, to-date, that our development the to Infection kinetics Annual analyzed to-date, continued Pharmacy difficile ex-vivo Infection. Scientific difficile to Houston at completed the at ibezapolstat analyses. Certain first-in-class The of marketed
Secondly, in terms year, November. scientific accepted of Conference in conferences Week Diff including the prominent Foundation the ID in upcoming September, Resistance three at highlights, Antimicrobial and this been ibezapolstat presentations Conference in have October, C. also later
of partnership by candidate initiated project Leiden multi-drug no classes needed. facilitate of optimize for in of where Xb at are as diff target binding of innovative acceleration outcome enrollment of project Fourth, we XXXX, collaboration and to The research University drug second Acurx's patient for the program, our bacteria, consortium support -- study and in Xa July Leiden patient continues further expected research program Acurx is with of data partner launched ACX-XXX Acurx intended C resistant three-dimensional interactions $XXX,XXX antibiotics development. polymerases, with to pipeline studying treatment grant are of September systemic pol where This company. program, program infection. completion to of our its Third, Phase in novel trial to patients classes pol our new by Medical DNA in with recent clinically was to an is has the inhibitors. accelerate urgently ibezapolstat of scientific The emerging selection ongoing This University preclinical DNA its with been in diff. development Medical our Gram-positive ibezapolstat's against new consortium structures IIIC XXX lead antibiotics Center enrollment their C. under 'XX, University validated in molecular Leiden antimycobacterial IIIC inhibitors, Center innovative Leiden our trial to our action University a product a mechanism with
XX-month our In involves into data. identified the potential investigators our study high prescribing commonly physicians used and clinical recent potential as treatment within program coordinators appropriate physicians sites. XX-month reaching each of principal Our referring antibiotics an of -- clinical newly case, from we've Diff IMS the most in radius sites, referring over trial C instituted the period from of identified XX-mile referring from physicians of trial approximate over our According to an activated physician XX for first referring a currently prescribing available to physician just is a to that available -- sites substantial suggesting sites one a of treated number industry XX could XX,XXX the patient total data potentially XX source, in period, the an the recent be of if us aggregate qualified. standard trial the patients of clinical in subjects for physicians trial referral
mitigating other up XX. the has enrollment, the of which of caused program by expand tranche COVID-XX to tranche has a from planned pandemic. elements with four our our or of participating believe followed XX this activated be year the to been mitigating clinical disruption first and as We potentially rate referring with countervailing of supportive enrollment the sites, partially program, a enhance The will physician this number is we sites second trial up later
participating in XX XX quarter from Phase onboarding. sites XX a Additionally, increased July and in active to Xb eight our more we sites up targeted number trial with the to reiterate, last from sites XXXX, trial clinical sites target now, of
will scientific additional target Our Xb six in team continue the to participate to sites trial trial. clinical
one of share, the invested stock, consummating proceeds represents 'XX, shares each has to a to pre-funded an particular. the of at common executives $X.XXX $X.XXX of three purchase warrant purchase common A common by Series basically July a exercise exercise institutional a success registered million with offering, we'll included means gross The another flows which which a X,XXX,XXX price, the pre-funded million for of company shares warrant price year $X.XX unregistered additional assuming door, company and for of XXX,XXX stock. one warrants, stock the issuing per common $X.XX and shares an warrants Xb warrants our Phase at aggregate shares the cash SEC, share and purchase registered common company's Series also $X.X investor about in stock not raised in a direct of in purchase no offering our that for shares B Finally, issued half to our B to The has investor a has us unless in X,XXX,XXX and the share which of of per price a another of X,XXX,XXX get the to with expiry trial.
some our highlights to interesting to you back guide Rob? Shawah, CFO, quarter stuffs the of Now, through about for the second Rob 'XX.
